Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

BACKGROUND: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of nirmatrelvir in preventing severe c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbel, Ronen, Wolff Sagy, Yael, Hoshen, Moshe, Battat, Erez, Lavie, Gil, Sergienko, Ruslan, Friger, Michael, Waxman, Jacob G., Dagan, Noa, Balicer, Ran, Ben-Shlomo, Yatir, Peretz, Alon, Yaron, Shlomit, Serby, Danielle, Hammerman, Ariel, Netzer, Doron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454652/
https://www.ncbi.nlm.nih.gov/pubmed/36001529
http://dx.doi.org/10.1056/NEJMoa2204919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454652/
https://www.ncbi.nlm.nih.gov/pubmed/36001529
http://dx.doi.org/10.1056/NEJMoa2204919

Ejemplares similares